These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26776524)

  • 1. Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.
    Duong-Ly KC; Devarajan K; Liang S; Horiuchi KY; Wang Y; Ma H; Peterson JR
    Cell Rep; 2016 Feb; 14(4):772-781. PubMed ID: 26776524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a potent dual ALK and EGFR T790M inhibitor.
    Jang J; Son JB; To C; Bahcall M; Kim SY; Kang SY; Mushajiang M; Lee Y; Jänne PA; Choi HG; Gray NS
    Eur J Med Chem; 2017 Aug; 136():497-510. PubMed ID: 28528303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
    Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
    Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer.
    Lu J; Zhou K; Yin X; Xu H; Ma B
    Comput Biol Chem; 2019 Feb; 78():290-296. PubMed ID: 30605854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel FLT3 kinase inhibitors.
    Pauwels D; Klaassen H; Lahortiga I; Kilonda A; Jacobs K; Sweron B; Corbau R; Chaltin P; Marchand A; Cools J
    Eur J Med Chem; 2013 May; 63():713-21. PubMed ID: 23567961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1.
    Malínková V; Řezníčková E; Jorda R; Gucký T; Kryštof V
    Bioorg Med Chem; 2017 Dec; 25(24):6523-6535. PubMed ID: 29089259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anchor-based classification and type-C inhibitors for tyrosine kinases.
    Hsu KC; Sung TY; Lin CT; Chiu YY; Hsu JT; Hung HC; Sun CM; Barve I; Chen WL; Huang WC; Huang CT; Chen CH; Yang JM
    Sci Rep; 2015 Jun; 5():10938. PubMed ID: 26077136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
    Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
    Kobayashi S; Ji H; Yuza Y; Meyerson M; Wong KK; Tenen DG; Halmos B
    Cancer Res; 2005 Aug; 65(16):7096-101. PubMed ID: 16103058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
    Sos ML; Rode HB; Heynck S; Peifer M; Fischer F; Klüter S; Pawar VG; Reuter C; Heuckmann JM; Weiss J; Ruddigkeit L; Rabiller M; Koker M; Simard JR; Getlik M; Yuza Y; Chen TH; Greulich H; Thomas RK; Rauh D
    Cancer Res; 2010 Feb; 70(3):868-74. PubMed ID: 20103621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).
    Chan S; Han K; Qu R; Tong L; Li Y; Zhang Z; Cheng H; Lu X; Patterson A; Smaill J; Ren X; Ding J; Xie H; Ding K
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4277-81. PubMed ID: 26259806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
    Tandon R; Kapoor S; Vali S; Senthil V; Nithya D; Venkataramanan R; Sharma A; Talwadkar A; Ray A; Bhatnagar PK; Dastidar SG
    Eur J Pharmacol; 2011 Sep; 667(1-3):56-65. PubMed ID: 21640718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR.
    Hegymegi-Barakonyi B; Eros D; Szántai-Kis C; Breza N; Bánhegyi P; Szabó GV; Várkondi E; Peták I; Orfi L; Kéri G
    Curr Opin Mol Ther; 2009 Jun; 11(3):308-21. PubMed ID: 19479664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
    Ai X; Sun Y; Wang H; Lu S
    Amino Acids; 2014 Jul; 46(7):1635-48. PubMed ID: 24658966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer.
    Ning J; Wu Q; Liu Z; Wang J; Lin X
    J Recept Signal Transduct Res; 2016; 36(1):37-44. PubMed ID: 26096169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation.
    Mishra RK; Alokam R; Singhal SM; Srivathsav G; Sriram D; Kaushik-Basu N; Manvar D; Yogeeswari P
    J Chem Inf Model; 2014 Oct; 54(10):2876-86. PubMed ID: 25254429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.